Abeona Therapeutics Inc.

Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing gene and cell therapies for rare genetic diseases. The company's primary objective is to harness the transformative power of gene therapy to address unmet medical needs. Specializing in innovative treatments, Abeona Therapeutics targets disorders such as recessive dystrophic epidermolysis bullosa (RDEB) and Sanfilippo Syndrome, aiming to provide long-term clinical benefits to patients with these debilitating conditions. Abeona employs advanced technologies including AAV-based gene therapy and a proprietary AIMTM capsid platform to deliver its therapeutic solutions. Playing a significant role in the biotechnology sector, the company contributes to the evolving landscape of genetic medicine by striving to bring cutting-edge treatments from research to clinical practice. Located in the U.S., Abeona Therapeutics is part of a dynamic market that seeks to improve patient outcomes through groundbreaking biological approaches, underscoring the vital role of biopharmaceuticals in shaping future healthcare solutions.